Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
about
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsIntegrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsStructure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorTKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsChange or die: targeting adaptive signaling to kinase inhibition in cancer cells.EGFR-mutated lung cancer: a paradigm of molecular oncology.Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells.Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsExosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cellsHsp90 molecular chaperone inhibitors: are we there yet?Sulforaphane attenuates EGFR signaling in NSCLC cellsAntitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.Heat shock protein 90 inhibition in lung cancer.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer.Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Broad targeting of resistance to apoptosis in cancer.The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
P2860
Q24339394-C0B1CEB6-51FE-487B-944B-FF3F2CB03844Q24614112-38D5EFAB-429C-4D98-A296-D2C267FA4BB2Q27014117-3FEDDA6F-E914-45CB-B7B6-D95C3FC8F842Q27851585-04A09FED-A324-4FC9-A2E1-B6CB16FE871CQ27851619-775289C0-37E6-40DA-819D-02D986478D9CQ28304273-164B8A57-2C55-414B-920C-1CC6D2668519Q30368961-27A0291B-A3D6-4E0D-852F-2E205909D0DBQ33397124-C3F70490-AAF5-46F8-9F1E-86C6DFDAD004Q33788708-AA5810C9-0832-4373-A7EB-465633E54E66Q33810574-EB9AE2DF-0A0B-4CE5-9BAC-140CD84D0A2BQ33911863-C8E67BB5-425E-4BC1-B970-01B0372A8196Q33943421-793F9776-E76B-476D-9507-ED78FA01F859Q33992604-864EA0CD-702B-4902-AD5D-B9070C86B5F2Q34000044-92E871A6-72B7-4246-9E30-C0955EBBC346Q34100283-8B9EC623-7D32-4636-91A5-1974B040B77FQ34165045-3873C62A-FF06-4127-8192-954E21FDCE6CQ34225871-8D4D08BC-2C94-44FB-A52F-4EBFF2C052ABQ34406334-215D661C-64AE-42B7-B584-F2B187B32AC3Q34570799-1CD0C768-BD8A-4A0F-9D3D-AEC38AE1766FQ34970672-A5561A53-02EB-47E3-B028-E005F0CB46E9Q34999744-0E32F9BA-A88C-491E-B4E6-1FA3AD272366Q35081010-CF4F7C0C-62C1-43FF-8A51-FDFD869AC83EQ35116206-87AF2ADB-505D-4DFA-A298-64E309FDF376Q35143602-434BC786-A7F7-4596-8707-5B314514FC63Q35168379-11F9B798-0012-4CCD-B1FD-4CB912E12FB9Q35188254-29355448-45BB-4824-9931-40CABD1EE2D1Q35655105-C8337189-A13D-413F-9C88-81E245C030DDQ35673332-47E62156-133F-423F-9ADC-29303E348A2EQ35688071-E30F1C84-9602-4B7F-9222-82234EAF495AQ35689752-3860BC0A-1616-4428-8EE8-CB1C34526F89Q35713152-AD541C32-2BB1-4F89-8BB3-DCEF88B36E22Q35762499-0F35AD13-3C6E-4A10-AC36-35781352C117Q35930811-8BBFF40A-9015-4B2F-8162-7326B22E96CBQ35994416-546E9154-5FC6-427E-A17D-70D9BD66E354Q36085503-FE7BE363-15AF-424F-9AAE-C3637ECAA614Q36200403-66C73C73-F42E-4279-9C3D-CA2D9FEF6959Q36336795-65647567-B6E9-4953-A29A-47CBB5BE0A98Q36465517-0C8F1B3E-1902-415D-9E45-8E17B30A5969Q36483749-16EFDD1A-0485-4381-892F-3389CF29A4B6Q36926960-E8FC114D-1864-404F-9C74-105A156EDB35
P2860
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Hsp90 inhibition suppresses mu ...... es kinase inhibitor resistance
@en
Hsp90 inhibition suppresses mu ...... s kinase inhibitor resistance.
@nl
type
label
Hsp90 inhibition suppresses mu ...... es kinase inhibitor resistance
@en
Hsp90 inhibition suppresses mu ...... s kinase inhibitor resistance.
@nl
prefLabel
Hsp90 inhibition suppresses mu ...... es kinase inhibitor resistance
@en
Hsp90 inhibition suppresses mu ...... s kinase inhibitor resistance.
@nl
P2093
P2860
P1433
P1476
Hsp90 inhibition suppresses mu ...... es kinase inhibitor resistance
@en
P2093
April M Lowell
Christa L Borgman
Daniel G Tenen
Elizabeth Liniker
Geoffrey I Shapiro
Henry J Haringsma
Hongbin Ji
Kate McNamara
Kwok-Kin Wong
P2860
P304
P356
10.1158/0008-5472.CAN-07-5428
P407
P577
2008-07-01T00:00:00Z